<DOC>
	<DOCNO>NCT00051623</DOCNO>
	<brief_summary>The purpose study determine Infliximab safe effective treatment psoriatic arthritis . Infliximab ( Remicade ) target specific proteins body 's immune system help control development inflammation help reduce painful disease .</brief_summary>
	<brief_title>A Study Safety Effectiveness Infliximab Treatment Psoriatic Arthritis</brief_title>
	<detailed_description>This phase III , multicenter , randomize ( patient assign different treatment base chance ) , double-blind ( neither patient physician know whether drug placebo take , dosage ) , placebo-controlled study design determine safety effectiveness Infliximab treatment patient psoriatic arthritis . This experimental medical research study . A total 200 people North America Europe participate study 17 month study period . Patients receive infusion either placebo 5 10 mg/kg infliximab ( Remicade ) week 0,2 , 6 , 14 , 16 , 18 , 22 , 30 , 38 , 46 . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive either placebo 5 mg/kg induction infusion ( week 0 , 2 6 ) follow maintenance infusion every 8 week week 46 . In placebo group , patient may early escape week 16 crossover week 24 infliximab ; . In 5mg/kg group , dose escalation need week 38 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosed psoriatic arthritis &gt; = 6 month active arthritis &gt; = 5 tender 5 swollen joint active psoriasis Have inflammatory disease , include limited , rheumatoid arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease Received systemic immunosuppressive within 4 week prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
</DOC>